Selected article for: "PEDV infection and vaccine candidate"
Author: Tien, Nguyen-Quang-Duc; Yang, Moon-Sik; Jang, Yong-Suk; Kwon, Tae-Ho; Reljic, Rajko; Kim, Mi-young
Title: Systemic and Oral Immunogenicity of Porcine Epidemic Diarrhea Virus Antigen Fused to Poly-Fc of Immunoglobulin G and Expressed in ΔXT/FT Nicotiana benthamiana Plants
  • Cord-id: omp7ppyi
  • Document date: 2021_4_30
    • ID: omp7ppyi
    Snippet: Porcine epidemic diarrhea virus (PEDV), a member of the Coronaviridae family has become increasingly probelmatic in the pig farming industry. Currently, there are no effective, globally applicable vaccines against PEDV. Here, we tested a recombinant PEDV vaccine candidate based on the expression of the core neutralising epitope (COE) of PEDV conjugated to polymeric immunoglobulin G scaffold (PIGS) in glycoengineered Nicotiana be nthamiana plants. The biological activity of COE-PIGS was demonstra
    Document: Porcine epidemic diarrhea virus (PEDV), a member of the Coronaviridae family has become increasingly probelmatic in the pig farming industry. Currently, there are no effective, globally applicable vaccines against PEDV. Here, we tested a recombinant PEDV vaccine candidate based on the expression of the core neutralising epitope (COE) of PEDV conjugated to polymeric immunoglobulin G scaffold (PIGS) in glycoengineered Nicotiana be nthamiana plants. The biological activity of COE-PIGS was demonstrated by binding to C1q component of the complement system, as well as the surface of antigen-presenting cells (APCs) in vitro. The recombinant COE-PIGS induced humoral and cellular immune responses specific for PEDV after both systemic and mucosal vaccination. Altogether, the data indicated that PEDV antigen fusion to poly-Fc could be a promising vaccine platform against respiratory PEDV infection.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • acute respiratory syndrome and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
    • acute respiratory syndrome and adcc cellular cytotoxicity: 1
    • acute respiratory syndrome and adjuvant effect: 1, 2, 3, 4, 5
    • acute respiratory syndrome and live currently inactivated: 1, 2
    • acute respiratory syndrome and livestock pathogen: 1, 2
    • acute respiratory syndrome and local ethics committee: 1, 2, 3, 4
    • acute respiratory syndrome and low affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory syndrome and low high affinity: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and luria bertani: 1
    • acute respiratory syndrome and lymphocyte proliferation: 1, 2, 3
    • adaptive innate and adcc cellular cytotoxicity: 1
    • adaptive innate and adjuvant effect: 1, 2, 3, 4, 5
    • adaptive innate and adjuvant saponin: 1, 2
    • adaptive innate and live currently inactivated: 1
    • adaptive innate and lymphocyte proliferation: 1, 2, 3, 4
    • adaptive innate immune response and adjuvant effect: 1, 2
    • adaptive innate immune response and lymphocyte proliferation: 1